Palatin Technologies, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PTN NYSE American 2836 palatin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Palatin Technologies, Inc.

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - Nov 12th, 2025 10:15 am
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - May 15th, 2025 1:16 am
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - May 14th, 2025 5:30 am
Biotech Alert: Searches spiking for these stocks today - May 10th, 2025 9:55 am
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - May 9th, 2025 5:30 am
Palatin Technologies Announces Closing of Reduced Public Offering - May 8th, 2025 8:19 pm
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - May 8th, 2025 2:30 pm
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - May 7th, 2025 6:26 pm
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - May 7th, 2025 6:15 am
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - May 7th, 2025 6:00 am
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy - May 5th, 2025 5:30 am
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease - Apr 29th, 2025 5:30 am
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - Apr 17th, 2025 5:30 am
Top Premarket Gainers - Apr 14th, 2025 6:48 am
Palatin Appeals NYSE American Notice of Delisting - Apr 14th, 2025 5:00 am
Top Midday Decliners - Apr 11th, 2025 12:29 pm
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - Apr 10th, 2025 2:01 pm
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - Apr 10th, 2025 5:30 am
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - Mar 31st, 2025 5:30 am
Palatin’s UC therapy prompts clinical remission in a third of patients - Mar 28th, 2025 11:11 am